Chimeric antigen receptor T-cell therapy can reduce tumor burden and improve neurologic function for patients with certain brain and spinal cord cancers, a first-in-human clinical trial showed. One young man — diagnosed at age 16 years with diffuse intrinsic pontine glioma — achieved complete response and remains healthy 4 years later. “Frankly, our results were jaw dropping,” Crystal L. Mackall, MD, Ernest and Amelia Gallo family professor of pediatrics and medicine at Stanford University School of Medicine and founding director of Stanford Center for Cancer Cell
CAR T-cell therapy produces ‘jaw dropping’ results for deadly pediatric brain tumors
Not classified
